Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Stock Issued for Financing Fee [Member] Common Stock [Member]	Stock Issued for Financing Fee [Member] Additional Paid-in Capital [Member]	Stock Issued for Financing Fee [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member] Additional Paid-in Capital [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2017						104,164,465
Balance at Dec. 31, 2017						$ 70,000	$ 97,093,000	$ (101,205,000)	$ (62,000)	$ 695,000	$ (3,409,000)
Issuance of common stock for services (in shares)						714,436
Issuance of common stock for services							196,000				196,000
Issuance of common stock for interest (in shares)						617,072
Issuance of common stock for interest							165,000				165,000
Financing fee in stock (in shares)	252,385
Financing fee in stock		$ 85,000	$ 85,000
Sale of stock for cash (in shares)						658,226
Sale of stock for cash							168,000				168,000
Stock option compensation expense							320,000				320,000
Warrants and beneficial conversion feature issued as discount on convertible notes payable, note payable and line of credit							282,000				282,000
Deemed dividend							297,000	(297,000)
Net loss								(2,323,000)		(107,000)	(2,430,000)
Foreign currency translation									8,000		8,000
Balance (in shares) at Mar. 31, 2018						106,406,584
Balance at Mar. 31, 2018						$ 70,000	98,606,000	(103,825,000)	(54,000)	588,000	(4,615,000)
Balance (in shares) at Dec. 31, 2017						104,164,465
Balance at Dec. 31, 2017						$ 70,000	97,093,000	(101,205,000)	(62,000)	695,000	(3,409,000)
Net loss											(8,410,000)
Foreign currency translation											(5,000)
Balance (in shares) at Sep. 30, 2018						132,036,574
Balance at Sep. 30, 2018						$ 86,000	108,213,000	(109,590,000)	(141,000)	375,000	(1,055,000)
Balance (in shares) at Mar. 31, 2018						106,406,584
Balance at Mar. 31, 2018						$ 70,000	98,606,000	(103,825,000)	(54,000)	588,000	(4,615,000)
Issuance of common stock for services (in shares)						733,821
Issuance of common stock for services							250,000				250,000
Issuance of common stock for interest (in shares)						1,302,734
Issuance of common stock for interest						$ 1,000	327,000				329,000
Sale of stock for cash (in shares)						617,145
Sale of stock for cash							212,000				212,000
Stock option compensation expense							376,000				376,000
Warrants and beneficial conversion feature issued as discount on convertible notes payable, note payable and line of credit							32,000				33,000
Net loss								(3,505,000)		(95,000)	(3,600,000)
Foreign currency translation									(7,000)		(7,000)
Conversion of notes (in shares)						19,298,723
Conversion of notes						$ 13,000	6,215,000				6,228,000
Warrant exercise price reduction for cash							149,000				149,000
Balance (in shares) at Jun. 30, 2018						128,359,007
Balance at Jun. 30, 2018						$ 84,000	106,167,000	(107,330,000)	(61,000)	493,000	(645,000)
Issuance of common stock for services (in shares)						691,791
Issuance of common stock for services							198,000				198,000
Issuance of common stock for interest (in shares)						83,062
Issuance of common stock for interest							21,000				21,000
Sale of stock for cash (in shares)						1,565,762
Sale of stock for cash						$ 1,000	444,000				445,000
Stock option compensation expense							288,000				288,000
Warrants and beneficial conversion feature issued as discount on convertible notes payable, note payable and line of credit							256,000				256,000
Net loss								(2,260,000)		(118,000)	(2,378,000)
Foreign currency translation									(80,000)		47,000
Conversion of notes (in shares)						1,336,952
Conversion of notes						$ 1,000	333,000				334,000
Warrant exercise price reduction for cash							506,000				506,000
Balance (in shares) at Sep. 30, 2018						132,036,574
Balance at Sep. 30, 2018						$ 86,000	108,213,000	(109,590,000)	(141,000)	375,000	(1,055,000)
Balance (in shares) at Dec. 31, 2018						141,466,071
Balance at Dec. 31, 2018						$ 95,000	110,222,000	(111,723,000)	(90,000)	373,000	(1,123,000)
Issuance of common stock for services (in shares)						1,229,541
Issuance of common stock for services						$ 1,000	205,000				206,000
Issuance of common stock for interest (in shares)						139,362
Issuance of common stock for interest							25,000				25,000
Stock option compensation expense							352,000				352,000
Warrants and beneficial conversion feature issued as discount on convertible notes payable, note payable and line of credit							1,115,000				1,115,000
Deemed dividend							342,000	(342,000)
Net loss								(2,576,000)		(173,000)	(2,749,000)
Foreign currency translation									(4,000)		(4,000)
Conversion of notes (in shares)						1,638,479
Conversion of notes						$ 1,000	218,000				219,000
Warrant exercise price reduction for cash				$ 56,000	$ 56,000
Issuance of Clyra Medical common stock							21,000			89,000	110,000
Balance (in shares) at Mar. 31, 2019						144,473,453
Balance at Mar. 31, 2019						$ 97,000	112,556,000	(114,641,000)	(94,000)	289,000	(1,793,000)
Balance (in shares) at Dec. 31, 2018						141,466,071
Balance at Dec. 31, 2018						$ 95,000	110,222,000	(111,723,000)	(90,000)	373,000	(1,123,000)
Net loss											(8,625,000)
Foreign currency translation											$ (1,000)
Warrant exercise (in shares)											3,166,666
Balance (in shares) at Sep. 30, 2019						158,671,346
Balance at Sep. 30, 2019						$ 106,000	119,421,000	(120,556,000)	(91,000)	110,000	$ (1,010,000)
Balance (in shares) at Mar. 31, 2019						144,473,453
Balance at Mar. 31, 2019						$ 97,000	112,556,000	(114,641,000)	(94,000)	289,000	(1,793,000)
Issuance of common stock for services (in shares)						981,684
Issuance of common stock for services							213,000				213,000
Issuance of common stock for interest (in shares)						87,478
Issuance of common stock for interest							15,000				15,000
Stock option compensation expense							296,000				296,000
Warrants and beneficial conversion feature issued as discount on convertible notes payable, note payable and line of credit							756,000				756,000
Deemed dividend							440,000	(440,000)
Net loss								(1,795,000)		(192,000)	(1,987,000)
Foreign currency translation									(4,000)		(4,000)
Conversion of notes (in shares)						2,767,833
Conversion of notes						$ 2,000	294,000				296,000
Issuance of Clyra Medical common stock							74,000			111,000	185,000
Warrant exercise (in shares)						3,744,456
Warrant exercise						$ 3,000	101,000				104,000
Stock issuance to officer (see note 7) (in shares)						500,000
Stock issuance to officer (see note 7)
Balance (in shares) at Jun. 30, 2019						152,554,904
Balance at Jun. 30, 2019						$ 102,000	114,745,000	(116,876,000)	(98,000)	208,000	(1,919,000)
Issuance of common stock for services (in shares)						629,198
Issuance of common stock for services							166,000				166,000
Issuance of common stock for interest (in shares)						395,944
Issuance of common stock for interest							107,000				107,000
Stock option compensation expense							552,000				552,000
Warrants and beneficial conversion feature issued as discount on convertible notes payable, note payable and line of credit							2,060,000				2,060,000
Net loss								(3,680,000)		(207,000)	(3,887,000)
Foreign currency translation									7,000		7,000
Conversion of notes (in shares)						2,791,300
Conversion of notes						$ 2,000	392,000				394,000
Issuance of Clyra Medical common stock							66,000			109,000	175,000
Warrant exercise (in shares)						2,300,000
Warrant exercise						$ 2,000	274,000				276,000
Convert BioLargo convertible note to Clyra Medical shares							440,000				440,000
Debt extinguishment expense							619,000				619,000
Balance (in shares) at Sep. 30, 2019						158,671,346
Balance at Sep. 30, 2019						$ 106,000	$ 119,421,000	$ (120,556,000)	$ (91,000)	$ 110,000	$ (1,010,000)